Targeting Persistent Human Papillomavirus Infection
AbstractWhile the majority of Human papillomavirus (HPV) infections are transient and cleared within a couple of years following exposure, 10–20% of infections persist latently, leading to disease progression and, ultimately, various forms of invasive cancer. Despite the clinical efficiency of recently developed multivalent prophylactic HPV vaccines, these preventive measures are not effective against pre-existing infection. Additionally, considering that the burden associated with HPV is greatest in regions with limited access to preventative vaccination, the development of effective therapies targeting persistent infection remains imperative. This review discusses not only the mechanisms underlying persistent HPV infection, but also the promise of immunomodulatory therapeutic vaccines and small-molecular inhibitors, which aim to augment the host immune response against the viral infection as well as obstruct critical viral–host interactions. View Full-Text
A printed edition of this Special Issue is available here.
Share & Cite This Article
Shanmugasundaram, S.; You, J. Targeting Persistent Human Papillomavirus Infection. Viruses 2017, 9, 229.
Shanmugasundaram S, You J. Targeting Persistent Human Papillomavirus Infection. Viruses. 2017; 9(8):229.Chicago/Turabian Style
Shanmugasundaram, Srinidhi; You, Jianxin. 2017. "Targeting Persistent Human Papillomavirus Infection." Viruses 9, no. 8: 229.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.